Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
Clinical trial NCT05125679 · TERMINATED
Trial details
- NCT number
- NCT05125679
- Sponsor
- Janssen-Cilag Ltd.
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-23
- Primary completion
- 2023-07-28
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.